Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

ohn Kearney, Ph.D., Distinguished Professor of Microbiology at the University of Alabama at Birmingham, has been named a 2023 Distinguished Fellow of the American Association of Immunologists.
Chronic pain often leads to depression, which increases suffering and is clinically difficult to treat. Understanding the underlying mechanism identifies a potential therapeutic target for treatment.
Diabetic retinopathy is the leading cause of blindness in American adults. The source of this damage may lie in the belly — mainly a leaky small intestine. A novel treatment can possibly prevent or reverse this damage.
The UALCAN data-mining portal at UAB has been used by cancer clinicians and researchers from more than 100 countries in their search for the molecular basis of cancer.
The spinoff company, IN8bio Inc., uses proprietary drug-resistant immunotherapy licensed in part from UAB. Glioblastoma is the most aggressive type of cancer originating in the brain.
High-resolution knowledge of structure is a key link between viral biology and potential therapeutic use of the virus to quell bacterial infections.
The first large multi-ancestry genetics study of osteoarthritis, or OA, has found 10 novel OA-associated genetic loci, and results showed some of the OA-associated regions are robustly found in every population ancestry studied.
Insights that are not possible with conventional two-dimensional platforms include characterization of obliterated airways in tuberculosis and hemorrhage from ruptured blood vessels in COVID-19 lungs, at near-microscopic levels.
Experimental neonatal chronic lung disease is marked by a redox imbalance that damages the lungs, and that damage can be ameliorated using a live biotherapeutic mixture of three Lactobacillus species.
This finding suggests utility of treatments before fecal microbial transplants to reduce recipient microbial communities. This would help donor microbial strains dominate in the recipient.
Page 1 of 45